Jeff Jones
Stock Analyst at Oppenheimer
(0.51)
# 3,829
Out of 4,759 analysts
85
Total ratings
13.7%
Success rate
-23.18%
Average return
Main Sectors:
Stocks Rated by Jeff Jones
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALMS Alumis | Initiates: Outperform | $32 | $4.88 | +555.74% | 1 | Jan 30, 2025 | |
| EVH Evolent Health | Maintains: Outperform | $28 → $18 | $8.99 | +100.22% | 4 | Jan 24, 2025 | |
| CLRB Cellectar Biosciences | Downgrades: Perform | n/a | $0.32 | - | 5 | Dec 11, 2024 | |
| CATX Perspective Therapeutics | Maintains: Outperform | $22 → $16 | $2.61 | +513.03% | 7 | Nov 22, 2024 | |
| YMAB Y-mAbs Therapeutics | Initiates: Outperform | $23 | $5.16 | +345.74% | 1 | Nov 18, 2024 | |
| CMMB Chemomab Therapeutics | Reiterates: Outperform | $13 → $11 | $1.25 | +780.00% | 7 | Nov 15, 2024 | |
| CRVS Corvus Pharmaceuticals | Reiterates: Outperform | $8 → $14 | $4.62 | +203.03% | 3 | Nov 13, 2024 | |
| VTYX Ventyx Biosciences | Reiterates: Outperform | $10 → $9 | $1.49 | +504.03% | 10 | Nov 8, 2024 | |
| KYMR Kymera Therapeutics | Maintains: Outperform | $52 → $56 | $32.89 | +70.26% | 4 | Sep 27, 2024 | |
| AVBP ArriVent BioPharma | Reiterates: Outperform | $35 → $39 | $21.87 | +78.33% | 2 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $87 → $89 | $29.80 | +198.66% | 1 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $45 | $1.62 | +2,677.78% | 6 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $88 | $6.79 | +1,196.02% | 8 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $0.77 | - | 4 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $21 | $1.26 | +1,566.67% | 2 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $1.31 | - | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $32 → $30 | $31.13 | -3.63% | 3 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $120 | $0.32 | +37,635.85% | 3 | May 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $1.91 | - | 2 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $15 | $1.23 | +1,119.51% | 5 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $75 | $1.12 | +6,596.43% | 2 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $1,600 → $1,100 | $1.88 | +58,410.64% | 2 | Nov 17, 2022 |
Alumis
Jan 30, 2025
Initiates: Outperform
Price Target: $32
Current: $4.88
Upside: +555.74%
Evolent Health
Jan 24, 2025
Maintains: Outperform
Price Target: $28 → $18
Current: $8.99
Upside: +100.22%
Cellectar Biosciences
Dec 11, 2024
Downgrades: Perform
Price Target: n/a
Current: $0.32
Upside: -
Perspective Therapeutics
Nov 22, 2024
Maintains: Outperform
Price Target: $22 → $16
Current: $2.61
Upside: +513.03%
Y-mAbs Therapeutics
Nov 18, 2024
Initiates: Outperform
Price Target: $23
Current: $5.16
Upside: +345.74%
Chemomab Therapeutics
Nov 15, 2024
Reiterates: Outperform
Price Target: $13 → $11
Current: $1.25
Upside: +780.00%
Corvus Pharmaceuticals
Nov 13, 2024
Reiterates: Outperform
Price Target: $8 → $14
Current: $4.62
Upside: +203.03%
Ventyx Biosciences
Nov 8, 2024
Reiterates: Outperform
Price Target: $10 → $9
Current: $1.49
Upside: +504.03%
Kymera Therapeutics
Sep 27, 2024
Maintains: Outperform
Price Target: $52 → $56
Current: $32.89
Upside: +70.26%
ArriVent BioPharma
Sep 10, 2024
Reiterates: Outperform
Price Target: $35 → $39
Current: $21.87
Upside: +78.33%
Aug 9, 2024
Reiterates: Outperform
Price Target: $87 → $89
Current: $29.80
Upside: +198.66%
Aug 8, 2024
Maintains: Outperform
Price Target: $48 → $45
Current: $1.62
Upside: +2,677.78%
Aug 7, 2024
Maintains: Outperform
Price Target: $80 → $88
Current: $6.79
Upside: +1,196.02%
Jun 7, 2024
Downgrades: Perform
Price Target: n/a
Current: $0.77
Upside: -
May 10, 2024
Maintains: Outperform
Price Target: $16 → $21
Current: $1.26
Upside: +1,566.67%
Apr 1, 2024
Reiterates: Perform
Price Target: n/a
Current: $1.31
Upside: -
Feb 29, 2024
Maintains: Neutral
Price Target: $32 → $30
Current: $31.13
Upside: -3.63%
May 25, 2023
Maintains: Outperform
Price Target: $120
Current: $0.32
Upside: +37,635.85%
May 23, 2023
Downgrades: Perform
Price Target: n/a
Current: $1.91
Upside: -
May 11, 2023
Reiterates: Outperform
Price Target: $15
Current: $1.23
Upside: +1,119.51%
Mar 24, 2023
Reiterates: Outperform
Price Target: $75
Current: $1.12
Upside: +6,596.43%
Nov 17, 2022
Maintains: Outperform
Price Target: $1,600 → $1,100
Current: $1.88
Upside: +58,410.64%